Qi, Wenqing <br/><br/>
AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.  [electronic resource] 

 -  International journal of cancer  Jun 2012 
 - 2997-3005 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.26324  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>Aurora Kinase B<br/>Aurora Kinases<br/>Benzimidazoles--pharmacology<br/>Cell Cycle--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Docetaxel<br/>Humans<br/>Lymphoma, B-Cell--drug therapy<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Mice<br/>Mice, SCID<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Taxoids--pharmacology<br/>Urea--analogs & derivatives<br/>Xenograft Model Antitumor Assays